Gasse Angela, Pfeiffer Heidi, Köhler Helga, Schürenkamp Jennifer
Institute of Legal Medicine, University Hospital Münster, Röntgenstr. 23, 48149, Münster, Germany.
Int J Legal Med. 2018 Jan;132(1):157-164. doi: 10.1007/s00414-017-1692-5. Epub 2017 Oct 5.
The ∆9-tetrahydrocannabinol (THC) metabolites 8β-hydroxy-THC and 8β,11-dihydroxy-THC are mentioned in the literature as potential blood markers of recent cannabis use. However, the formation of these metabolites in in vivo detectable concentrations has been described controversially. Therefore, the aim of this study was to verify the in vivo metabolism of 8β-hydroxy-THC and 8β,11-dihydroxy-THC in order to evaluate their potential as blood markers of recent cannabis use. First, we developed and validated a solid-phase-extraction method coupled with gas chromatography-mass spectrometry in order to enable the selective and very sensitive determination of 8β-hydroxy-THC and 8β,11-dihydroxy-THC. The application of this method in the analysis of 70 authentic plasma samples of cannabis users revealed positive results for both analytes. We detected 8β-hydroxy-THC in three and 8β,11-dihydroxy-THC in 37 out of the 70 analyzed samples. For 8β-hydroxy-THC, all of the three positive results were below the limit of quantification (LOQ; 0.3 ng/mL) but above the limit of detection (LOD; 0.2 ng/mL). For 8β,11-dihydroxy-THC, only two positive results were below the LOQ (0.4 ng/mL) but above the LOD (0.3 ng/mL); the remaining 35 were quantified. Hence, we were able to prove the in vivo metabolism from THC to both 8β-hydroxy-THC and 8β,11-dihydroxy-THC in detectable concentrations. The quantitative comparison of 8β-hydroxy-THC and 8β,11-dihydroxy-THC with the main cannabinoids THC, 11-hydroxy-THC, and 11-nor-9-carboxy-THC revealed no further informative value for 8β-hydroxy-THC regarding the last time of cannabis consumption. However, the detectability from 8β,11-dihydroxy-THC compared to 11-hydroxy-THC suggests a shorter detection time for 8β,11-dihydroxy-THC and thereby a promising application of this metabolite as a blood marker of recent cannabis use.
文献中提到,∆9-四氢大麻酚(THC)的代谢物8β-羟基-THC和8β,11-二羟基-THC是近期使用大麻的潜在血液标志物。然而,关于这些代谢物在体内可检测浓度下的形成情况,文献描述存在争议。因此,本研究的目的是验证8β-羟基-THC和8β,11-二羟基-THC的体内代谢情况,以评估它们作为近期使用大麻血液标志物的潜力。首先,我们开发并验证了一种固相萃取方法,并结合气相色谱-质谱联用技术,以便能够选择性且非常灵敏地测定8β-羟基-THC和8β,11-二羟基-THC。将该方法应用于分析70份大麻使用者的真实血浆样本,两种分析物均得到阳性结果。在70份分析样本中,我们检测到3份含有8β-羟基-THC,37份含有8β,11-二羟基-THC。对于8β-羟基-THC,所有3个阳性结果均低于定量限(LOQ;0.3 ng/mL)但高于检测限(LOD;0.2 ng/mL)。对于8β,11-二羟基-THC,只有2个阳性结果低于定量限(0.4 ng/mL)但高于检测限(0.3 ng/mL);其余35个结果得到了定量。因此,我们能够证明在可检测浓度下,THC在体内可代谢生成8β-羟基-THC和8β,11-二羟基-THC。将8β-羟基-THC和8β,11-二羟基-THC与主要大麻素THC、11-羟基-THC和11-去甲-9-羧基-THC进行定量比较后发现,8β-羟基-THC对于确定最后一次使用大麻的时间并无更多参考价值。然而,与11-羟基-THC相比,8β,11-二羟基-THC的可检测性表明其检测时间较短,因此这种代谢物有望作为近期使用大麻的血液标志物。